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Abstract 1 
Background: Citrulline malate (CM) is purported to buffer lactic acid, enhance 2 
oxygen delivery, and attenuate muscle soreness. Anaerobic exercise trials with CM 3 
have produced conflicting results. Objective: The aim of the current investigation 4 
was to test the efficacy of CM on resistance training (RT) with the hypothesis that CM 5 
would improve performance. Design: A double-blind, counter-balanced, randomised 6 
control trial was utilised to assess the effects of CM on RT. 19 subjects (8 female) 7 
(25.7 ± 7.7 years), regularly engaged in RT consumed either 8 g of CM (1.1 : 1 ratio) 8 
or a placebo (6 g citric acid). Subjects attempted to perform a German Volume 9 
Training (GVT) protocol comprising 10 sets of 10 repetitions of barbell curls at 80 % 10 
of their one repetition maximum.  Results: Repeated ANOVA suggested no effect of 11 
CM on RT performance (treatment × time × order p = 0.217). There was no 12 
difference (p = 0.320) in the total number of reps over the ten sets (CM median = 57, 13 
IQR 45 to 73; placebo median = 61, IQR 51 to 69). Blood lactate and creatine kinase 14 
did not differ between CM and placebo (p > 0.05). Finally, total muscle soreness was 15 
reduced significantly in CM compared to placebo (treatment × time × order p = 0.004).  16 
Conclusions: These results require corroboration; an ergogenic benefit is yet to be 17 
established and weight trainers should exercise caution when assessing the efficacy 18 
of CM. Future research should focus on the potential effects of loading doses of CM. 19 
Keywords: Resistance Training, Supplementation, Muscle Soreness, Arginine, 20 
Creatine Kinase, NOS  21 
  22 
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Introduction 23 
Citrulline (CIT) is a non-essential amino acid, which acts as a nitrogen ion acceptor 24 
from carbamoyl-phosphate within the urea cycle. The dietary supplement citrulline 25 
malate (CM) has been purported to improve aerobic and anaerobic exercise 26 
performance via a variety of mechanisms including improved ammonia, arginine and 27 
lactic acid metabolism, alongside an increase in ATP production (da Silva et al., 28 
2018). Increasing muscle CIT may attenuate ammonia accumulation resulting in a 29 
lactic acid buffer effect, which might enhance subsequent recovery, attenuate fatigue 30 
and reduce post exercise muscle soreness (Ochia et al., 2012; Cutufrello et al., 31 
2015).  Ammonia influences fatigue by stimulating phosphofructokinase, leading to 32 
an increased rate of glycolysis (Takeda et al., 2011). This may increase blood lactic 33 
acid during exercise inhibiting pyruvate oxidation leading to hydrogen ion 34 
accumulation, and a reduction in muscle pH, and contractile potential (Cutufrello et 35 
al., 2015).  36 
Citrulline is also adjacent to arginine succinate in the urea cycle, and can be directly 37 
synthesised to arginine. Studies have demonstrated that supplementation with CIT 38 
increases circulating levels of arginine, which may simultaneously acting as a lactic 39 
acid buffer, and vasodilator via nitric oxide synthase (Takeda et al., 2011; Cutufrello 40 
et al., 2015; Martinez-Sanchez et al., 2017). Trials have demonstrated that blood 41 
arginine increases to a greater extent with oral CIT than arginine  due to splanchnic 42 
extraction (Moinard et al., 2008; Sureda et al., 2010; Takeda et al., 2011; Wijnands et 43 
al., 2015). By way of comparison, a 0.75 g twice daily oral dose of CIT resulted in 44 
similar increase in blood arginine compared to a 1.6 g twice daily dose of arginine 45 
(Schwedhelm et al., 2007). Finally, malate acid is combined with CIT to form the salt 46 
CM. Malate is an intermediate in the TCA cycle, and increasing the pool size of 47 
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intermediates may theoretically increase oxidative ATP (Thomas et al., 2004), 48 
although to date, no trials have investigated the performance enhancing effects of 49 
malate.  50 
Citrulline malate as an ergogenic aid and has become of interest to exercise 51 
scientists in recent years, with studies suggesting conflicting effects on exercise 52 
performance (Bendehan et al., 2002; Perez-Guisda and Jakeman 2010; Wax et al., 53 
2015; Wax et al., 2016; Farney et al., 2017; Glenn et al., 2017; da Silva et al., 2018). 54 
However, some evidence suggests an acute dose of 6-8 g of CM improves 55 
resistance training (RT) performance (Perez-Guisda and Jakeman 2010; Wax et al., 56 
2015; Wax et al., 2016; Glenn et al., 2017) and aerobic energy production (Bendehan 57 
et al., 2002).  More recently however, studies using similar dosages and comparable 58 
RT protocols have found no effect (Farney et al., 2017; da Silva et al., 2018). The 59 
aim of the current investigation was to assess the effects of CM on German Volume 60 
Training (GVT) performance to elucidate its efficacy of this potential ergogenic aid. 61 
We hypothesised that supplementation with CM would increase the total amount of 62 
work performed during repeated bouts of exercise. 63 
 64 
Subjects and Methods 65 
Subjects 66 
Twenty one subjects volunteered to participate in this study. Two females dropped 67 
out, without citing a reason for doing so, leaving 12 males and 7 females who 68 
completed the study. Table 1 displays the subject characteristics. Subjects were 69 
recruited from Sheffield Hallam University campus via posters, and word of mouth. 70 
All subjects were healthy, non-smokers, free from injury and any underlying health 71 
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conditions, and not currently using medication or taking supplements containing CM. 72 
Subjects were advised to follow their normal diet and supplement regime for the 73 
duration of their involvement in the trial, to avoid strenuous exercise 48 h pre and 74 
post laboratory visits and to maintain their regular exercise schedule post 48 h.  All 75 
subjects were at least "moderately resistance trained" defined as following a 76 
structured RT programme at least twice per week, for the last 6 months. Written 77 
consent was obtained from all subjects prior to taking part in the trial. The Sheffield 78 
Hallam University Business School Food Research Ethics Committee approved the 79 
trial.   80 
(Table one approx. here) 81 
 82 
Experimental Design 83 
A randomised double-blind placebo cross-over design was implemented. Each 84 
subject reported to the laboratory on three separate occasions 7 days apart. Subjects 85 
were randomised to either CM or placebo using a random number generator and an 86 
independent researcher (JG) performed concealment. The treatments were 87 
counterbalanced and blinding was revealed on completion of the trial. On the first 88 
visit subjects had, the GVT protocol and the muscle soreness visual analogue scale 89 
(VAS) explained to them. Subjects then performed a bicep barbell curl one rep 90 
maximum (1RM) test, used to calculate 80% 1RM used for the GVT. 91 
On the second and third visits, subjects arrived fasted to the laboratory, provided a 92 
blood sample and then consumed either 8 g of CM or a placebo which were both 93 
provided as sports drinks. Subjects then completed a 24 h dietary recall and baseline 94 
muscle soreness VAS was recorded. One hour after consuming the sports drink, 95 
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subjects performed the GVT barbell curl protocol (10 sets to failure with a maximum 96 
of 10 repetitions per set, one-minute rest between sets). The total number of 97 
repetitions was counted across each set, and failure was determined when a full 98 
range of motion could no longer be completed. Following the GVT a second blood 99 
sample was taken, subjects then completed the muscle soreness VAS and then 100 
again at 24, 48 and 72 h. The following week subjects completed the trial under the 101 
opposite treatment condition. 102 
 103 
Anthropometrics and Muscle Soreness Scale 104 
Height and weight were assessed using a stadiometer (Holtain, Crymych, United 105 
Kingdom) and column scale (Seca, Birmingham, United Kingdom), body composition 106 
via bioelectrical impedance (Bodystat 1500, Douglas, Isle of Man) and body mass 107 
index (BMI) was calculated kg/m2. Muscle soreness was scored using a 100 mm 108 
VAS at four sites on the upper and lower arm (Biceps brachii: long and short head 109 
and Brachioradialis and Flexor carpi radialis). On the VAS 0 indicated no pain, and 110 
100 indicated the worst pain imaginable. The sum of the four sites was combined and 111 
used to represent total soreness at each time point. Muscle soreness was recorded 112 
immediately pre and post exercise under supervision and self-assessed at 24, 48 113 
and 72 h following GVT. A demonstration of how to self-palpate and score the 114 
muscle soreness was provided by the researchers along with an instruction sheet 115 
with diagrams detailing the points of palpation.  The research team reminded the 116 
subjects to complete muscle soreness VAS at the same time of day using both text 117 
message and email prompts. 118 
 119 
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Supplementation Protocol 120 
Subjects were provided with either 8 g of CM (1.1:1 ratio, 4.2 g citrulline, 3.8 g malate, 121 
Bulk Powders, United Kingdom), or a placebo 6 g of citric acid (Sigma-Aldrich, Dorset, 122 
United Kingdom). Both placebo and supplement drinks were mixed in 70 ml of fruit 123 
cordial and 150 ml of water and consumed within 5 minutes. The dosages and timing 124 
of the CM were based on research showing that peak CIT levels occur 1 h after 125 
administration (Moinard et al., 2008). The CM and placebo drinks were both well 126 
tolerated, and subjects reported no side effects. 127 
 128 
Assessment of Supplement Quality 129 
Determination of the supplement quality was assessed using nuclear magnetic 130 
resonance (NMR) spectroscopy. The CM utilised in the present investigation had a 131 
purported ratio of 2:1 citrulline to malate (Bulk Powders, United Kingdom). Briefly, a 132 
standard NMR tube containing 100 mg of the CM supplement powder was added to 133 
1 mL of D2O (Fisher Scientific, UK). The sample was then warmed to 40 °C and 134 
agitated to ensure complete dissolution of the solid for analysis of the total organic 135 
fraction. Once the solid was dissolved, the solution was cooled to room temperature 136 
and analysed on a Bruker Avance DPX-400 NMR spectrometer operating at 137 
resonance frequencies of 400 MHz (1H) and 100 MHz (13C). All 1H and 13C NMR 138 
chemical environments in both CIT and malic acid were unambiguously assigned 139 
using 1H, 1H–COSY, 13C, DEPT–135, HSQC and HMBC experiments. The 1H NMR 140 
signals were then integrated, with the signal resulting from H9 on malic acid (at ∂ = 141 
4.37 ppm) being calibrated as 1. The integration values for the triplicate runs were 142 
then calculated.  All possible comparisons of integral values between chemical 143 
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environments in CIT and those in malate were then performed and the mean nuclear 144 
ratios for each individual replicate were then compiled into overall mean and 145 
standard deviation values, which represent the citrulline:malate molar ratio calculated 146 
from 8 individual data comparisons and three total experimental repeats. 147 
 148 
German Volume Training and One Rep Max Testing 149 
The 1RM testing protocol was carried out in accordance with the recommendations 150 
of the National Strength and Conditioning Association (2015). 48 hours prior to and 151 
48 h after each visit to the laboratory subjects were asked to refrain from all 152 
strenuous exercise. Subjects fasted and avoided caffeine intake on the morning of 153 
testing. Both GVT sessions were performed at the same time of day (± 1 h), 7 days 154 
apart, and under the same laboratory environmental conditions (21ºC, 45 - 55% 155 
Relative Humidity).   One hour after consuming the sports drink subjects completed a 156 
warm-up (5 min brisk walk followed by 3 sets of barbell curls with no weight on the 157 
bar) before proceeding with the GVT consisting of 10 sets, of 10 repetitions of barbell 158 
curls at 80 % of the subjects 1RM, with 60 s rest between sets. The numbers of 159 
complete repetitions performed for each set were recorded with the set terminating 160 
when the subject could no longer complete a full repetition, full repetitions were 161 
determined by one of the investigators (TS).    162 
 163 
Blood Sampling, Lactate and Creatine Kinase Analysis  164 
Prior to the GVT exercise protocol, subjects reported to the laboratory and rested for 165 
10 minutes in a seated position. Immediately after the GVT a second blood sample 166 
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was obtained. Blood samples were obtained via finger prick using a lancet (Accu-167 
chek, Safe-T-Pro). A 20 цl blood sample was taken with a capillary tube and added to 168 
an Eppendorf containing heparin and saline lactate was then read immediately using 169 
a Biosen C-line (EKF Diagnostics, Ebendorfer, Germany). Creatine kinase (CK) was 170 
measured via a 30 μL capillary sample collected pre and post-exercise in Microsafe 171 
Collection and dispensing tube (Inverness Medical, Cheshire, UK) and applied 172 
immediately to a Reflotron Creatine kinase  strip (Refletron Plus clinical chemistry 173 
analyser; Woodley Laboratory Diagnostics, Bolton, United Kingdom). 174 
 175 
Dietary Intake and Analysis 176 
Subjects were instructed to consume similar foods the day before testing and refrain 177 
from starting/stopping any new dietary/supplement regimes for the duration of their 178 
involvement in the trial. Prior to taking part in the GVT subjects completed a 24 h 179 
dietary recall.  Nutritics (version 2017, Dublin, Ireland) dietary analysis software was 180 
used to analyse the data (see Table 2). Nutrition data was adjusted for bodyweight 181 
and expressed as grams and calories per kg of bodyweight. 182 
 183 
Statistics 184 
All data were analyzed using SPSS (IBM, version 24). The main outcome measure, 185 
RT performance during GVT, was analysed using a 2 condition (CM and placebo) 186 
repeated measures analysis of variance to determine any differences in performance 187 
over the ten sets (treatment × time). Treatment order was added to the model as a 188 
covariant (treatment × time × order). Muscle soreness was analysed in the same way, 189 
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using the sum of the 4-site muscle soreness VAS for each time point. Mauchly's test 190 
of sphericity was applied to determine sphericity, where this was violated; the 191 
Greenhouse-Geisser estimate was used. Data for blood lactate, CK, total reps (the 192 
sum of all repetitions across all 10 GVT sets), and dietary intake were assessed for 193 
normality using the Kolmogorov-Smirnov test. A paired sample t-test or Wilcoxon 194 
Signed Rank test was used as appropriate, when data met the requirements for 195 
parametric or non-parametric testing. Statistical significance was established at p < 196 
0.05. Where data was normally distributed it is presented as means, standard 197 
deviation and 95 % confidence interval (CI). For non-normally distributed data the 198 
median and the inter-quartile range were presented.  199 
 200 
Results 201 
Analysis of dietary recall indicated no difference (p > 0.05) in macronutrient or energy 202 
intake, between CM and placebo conditions (Table 2). Subjects confirmed that they 203 
did not stop or start any new supplements over the duration of the trial. Determination 204 
of the citrulline to malate ratio revealed the supplement contained a 1.1:1 ratio 205 
citrulline to malate rather than the purported 2:1 ratio advertised on the back of the 206 
packaging. Resistance training performance during the GVT is presented in Figure 1.  207 
There was no significant difference, between the CM and placebo condition, on GVT 208 
performance, measured by repetitions performed per set (treatment × time p = 0.174). 209 
Treatment order had no effect on GVT performance (treatment × time × order p = 210 
0.217). There was a significant effect of time (p < 0.001) on GVT performance, e.g. 211 
the number of repetitions performed declined as sets progressed (mean repetitions 212 
set 1, placebo 9.8 ± 0.7 vs CM 9.5 ± 1.1; set 10, placebo 4.4 ± 2.9 vs CM 4.6 ± 2.4).  213 
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There was no statistically significant difference (Z = 0.995, p = 0.320) in the total 214 
number of repetitions achieved over the ten sets of GVT between the CM (median = 215 
57, IQR 45 - 73) and placebo conditions (median = 61, IQR 51 - 69). 216 
(Table 2, and Figure 1 approx. here) 217 
Blood lactate data is presented in Figure 2. Lactate increased significantly (p < 0.001) 218 
post GVT in both the CM (mean lactate pre, 1.9 ± 0.6, post 4.7 ± 2.0 mM) and 219 
placebo conditions (mean lactate pre, 1.8 ± 0.6, post 4.9 ± 1.7 mM). There was 220 
however, no difference (t = 0.434 p = 0.670) in the magnitude of change in lactate 221 
post GVT between CM and placebo with a mean increase of 3.01 mM (95 % CI 2.41 222 
- 3.62). There was no difference in CK levels post GVT under the CM treatment (pre, 223 
172 I/U IQR 48.5 - 222.9; post, 179.00 IQR 149.5 - 370.4, Z = 1.552, p = 0.121), 224 
however there was a difference under the placebo condition (pre, 145 I/U IQR 52.9 - 225 
333.0; post, 219 IQR 91.1 - 423.2, Z = 1.991, p = 0.046). The median difference of 226 
the differences the subjects for CK pre to post exercise did not differ (Z = 0.052, p = 227 
0.959) between CM (median = 66.1 I/U IQR 34.3 - 152.6) or the placebo condition 228 
(median = 60.4 I/U IQR 19.3 - 150.0). 229 
(Figure two approx. here) 230 
The effect of CM on 72 h muscle soreness is detailed in Figure 3. Muscle soreness 231 
was significantly higher in the placebo compared to the CM treatment over 72 h 232 
(treatment × time p = 0.004). The statistical difference was maintained when 233 
treatment order was included in the model (treatment × time × order p = 0.008).  234 
(Figure three and table two approx. here) 235 
Discussion 236 
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In the current investigation, we hypothesised that an acute dose of CM prior to an 237 
exercise session would increase the total amount of work performed during GVT. 238 
Citrulline malate had no effect on GVT performance, blood lactate or CK compared to 239 
a placebo, although subjects did report an overall reduction in muscle soreness. The 240 
results of the present investigation accept the null hypothesis and are in agreement 241 
with recent findings showing no effect of CM on RT performance (Farney et al., 2017; 242 
Chappell et al. 2018; da Silva et al., 2018,). Moreover, these findings are in contrast 243 
to others who have identified an effect of CM with RT (Wax et al., 2015; Wax et al., 244 
2016; Glenn et al., 2017). Specifically, Perez-Guisda and Jakeman (2010) and Wax 245 
et al., (2016) reported a 13 and 12.5 % respectively, increase in the number of 246 
repetitions achieved after consecutive bouts of RT following CM supplementation.  247 
By way of comparison, a similar increase would have amounted to an 8-repetition 248 
difference in the total repetitions between the CM and placebo condition in the 249 
present investigation.  250 
The reduction in soreness identified with CM was accompanied by a lack of 251 
difference in the total amount of work performed between treatment groups. This 252 
could lead to the conclusion that less soreness was elicited from the same workload 253 
when the subjects consumed CM. Although we note that subjects did not report high 254 
values for muscle soreness pre or post exercise, which may reflect the nature of the 255 
exercise i.e only small muscle groups were involved in our protocol. da Silva et al. 256 
2017 and Chappell et al. 2018, both found a greater degree of soreness, this seems 257 
to be commensurate with protocols involving larger muscle groups. We also note a 258 
lack of any immediate difference in CK or lactate levels between conditions, which 259 
might be expected to accompany any difference in soreness. The lack of change, in 260 
these markers or muscle damage and exercise intensity is in agreement with recent 261 
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trials utilising CM during RT protocols (Wax et al., 2015; Wax et al., 2016; da Silva et 262 
al., 2017; Farney et al., 2017). Effects of CM on muscle soreness and RT have so far 263 
produced mixed results, with both reductions in soreness (Perez-Guisado & Jakeman 264 
2010) and no difference when compared to placebo (da Silva et al., 2017; Chappell 265 
et al., 2018). Curiously, trials of aerobic exercise have so far indicated a reduction in 266 
soreness utilising CM (Tarozona-Diaz et al., 2013, Martinez-Sanchez et al., 2017). 267 
Potential explanations for a reduction in soreness therefore may be attributed to 268 
CIT's role in the urea cycle and the augmented clearance of ammonia (Callis et al., 269 
1991).   270 
Finally, we sought to corroborate the level of the active ingredient used in the present 271 
investigation with the manufacturer's labelling. The data suggests that the amounts of 272 
active ingredient in the supplement varied, by almost half, from the manufacturers 273 
labelling. The dosage consumed by subjects was 4.2 g CIT and 3.8 g malate (1.1:1 274 
ratio) instead of the intended 6 g CIT and 2 g malate (2:1 ratio). A previous 275 
investigation reported similar findings from five "over the counter" CM supplements 276 
(Chappell et al., 2018).The disparity between the actual and intended dosage may 277 
account for a lack of significant findings. Moinard et al., (2008) however, reported a 278 
significant increase in plasma CIT using a similar dosage to the one used in the 279 
present investigation. Moreover, the data highlights the need for researchers to 280 
conduct analyses of supplement quality prior to publishing trials. Caution therefore 281 
needs to be taken when assessing any dose-response study using commercial CM 282 
supplements. Commercial supplements, however, are the products recreationally 283 
active individuals and athletes alike use in an attempt to aid recovery and improve 284 
performance. 285 
 286 
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Strengths and Limitations 287 
A counterbalanced design was employed to account for a potential training effect, 288 
and statistical analysis identified that subjects did not perform better on their second 289 
GVT session compared to the first. There was also no difference in dietary intake for 290 
the 24 hours preceding testing, between the CM and placebo conditions, Therefore 291 
any lack of statistical finding may not be attributed to a disparity in diet (e.g. an 292 
increased carbohydrate or energy intake between conditions).  293 
The investigation did not include a measure of ammonia to accompany the data 294 
gathered on lactate and CK to corroborate the difference in muscle soreness. 295 
Furthermore, although we advised subjects to rest 48 h prior to commencing the trial, 296 
several subjects had elevated CK suggesting engagement in prior exercise.  297 
Increases in CK levels in response to exercise are known to be highly variable and 298 
increase significantly in days following exercise (Ehlers et al. 2002). Creatine kinase 299 
was only measured immediately post exercise and a measurement taken alongside 300 
muscle soreness over 72 h would have elucidated the recovery process more clearly. 301 
Moreover, measurements of muscle soreness were self-reported between the 24-72 302 
h measures potentially and supervised measures would have been preferable. The 303 
subjects involved in the present investigation were not a homogenous group. 304 
Training experience varied and no controls were put in place to account for the 305 
impact of menstrual cycling. Finally, we utilised citric acid as a placebo condition. We 306 
only found a single study focused on the effect of citric acid on exercise. Sugino et al. 307 
(2007) utilised an 8 day loading protocol combined with aerobic exercise, the authors 308 
found no effect on performance, blood citric acid or lactate levels. The placebo was 309 
effective at replicate the taste of CM and was well tolerated.   310 
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Subjects completed the trial fasted to eliminate the influence of feeding on 311 
performance. We could alternatively have included a standardised breakfast in the 312 
protocol to reflect the probability that exercise is often not carried out in a fasted state.  313 
Finally, we asked the participants not to stop or start any other supplement intake for 314 
the duration of the trial and a condition of participation was that they weren't taking 315 
any supplements containing CM. Although we acknowledge the potential effects of 316 
other supplements on performance the crossover design of this study to some extent 317 
mitigates against this. Secondly we are reminded of the real-world nature of 318 
supplement intake whereby in reality people will not postpone ongoing 319 
supplementation regimes when they begin new ones.  320 
 321 
Conclusion 322 
An acute dose of 8 g CM (1.1:1 ratio) did not confer any benefits to the main outcome 323 
measure of RT performance, in a moderately trained group. Total muscle soreness 324 
was reduced over the 72 h following CM treatment however; both CK and lactate 325 
were unaffected immediately following exercise.  This is the first study to date to test 326 
the effectiveness of CM using a GVT free weight exercise protocol. Further trials on 327 
acute and chronic use of CM are warranted to confirm or deny its effectiveness as an 328 
ergogenic aid. Athletes and coaches should proceed with caution when deciding 329 
whether to utilise CM as part of a supplementation protocol; the present study and 330 
current literature is mixed and recommendation of CM as an anaerobic ergogenic aid 331 
is not warranted based on the present results, although we note with caution there 332 
may be a positive effect on muscle soreness. Finally, in light of our findings, future 333 
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researchers should endeavour to carry out chemical analysis to ensure the validity of 334 
treatment dose. 335 
 336 
Acknowledgements 337 
The study was designed and conducted by TNS and AJC: data was collected by TNS, 338 
and AJC, analysis of the data and interpretation was carried out by TNS and AJC. Dr. 339 
Daniel M Allwood carried out analysis of the dietary supplement via NMR and 340 
contributed to the method section of the manuscript. Manuscript preparation was 341 
undertaken by TNS and AJC. All authors approved the final version of the paper. The 342 
authors would like to acknowledge Dr. Jeanette Gittens for blinding and 343 
counterbalancing the supplement/placebo in this investigation. The authors would 344 
also like to acknowledge Mr. Adrien Parry for his assistance during the data 345 
collection. The authors declare no conflict of interest. This study had prior approval 346 
from the Sheffield Hallam University Food Research Ethics Committee No; SBS - 347 
252.348 
17 
 
 
References  
Bendahan D, Mattei JP, Ghattas B, Confort-Gouny S, Le Guern ME,  Cozzone PJ. 
2002. Citrulline/malate promotes aerobic energy production in human exercising 
muscle. Brit J Sport Med. 36(4): 282-289. 
Callis A, de Bornier Magnan B, Serrano JJ, Bellet H, Saumad, R. 1991. Activity of 
citrulline malate on acid-base balance and blood ammonia and amino acid levels. 
Study in the animal and in man. Arzneimittelforschung. 41(6): 660-663. 
Chappell AJ, Johns R, Simper TN 2018. Citrulline malate has no effect on German 
volume training protocol. Int J Sport Nutr Exe. 28: S1-11.  
Chappell AJ, Allwood DM, Johns R, Brown S, Sultana K, Anand A, Simper S. 2018. 
Citrulline Malate Supplementation Does Not Improve German Volume Training 
Performance or Reduce Muscle Soreness in Moderately Trained Males and Females. 
JISSN under review. 
Cunniffe B, Papageorgiou M, O'Brien B, Davies NA, Grimble GK, Cardinale M. 
(2016). Acute citrulline-malate supplementation and high-intensity cycling 
performance. J Strength Cond Res. 30(9): 2638-2647. 
Cutrufello PT, Gadomski SJ, Zavorsky GS. 2015. The effect of l-citrulline and 
watermelon juice supplementation on anaerobic and aerobic exercise performance. J 
Sport Sci. 33(14): 1459-1466. 
da Silva DK, Jacinto JL, de Andrade WB, Roveratti MC, Estoche JM, Balvedi MC, de 
Oliveira DB, da Silva RA, Aguiar AF. 2018. Citrulline malate does not improve muscle 
18 
 
recovery after resistance exercise in untrained young adult men. Nutrients, 9 (10): 
1132. 
Ehlers GG, Ball TE, Liston L. 2002. Creatine kinase levels are elevated during 2-a-
day practices in collegiate football players. J Athl Train, 37(2): 151-156. 
El-Hattab AW, Hsu JW, Emrick LT, Wong LJC, Craigen WJ, Jahoor F, Scaglia F. 
2012. Restoration of impaired nitric oxide production in MELAS syndrome with 
citrulline and arginine supplementation.  Mol Genet Metab, 105(4): 607-614. 
Farney TM, Bliss MV, Hearon CM, Salazar DA, 2017. The effect of citrulline malate 
supplementation on muscle fatigue among healthy participants. J Strength Cond Res, 
DOI: 10.1519/JSC.0000000000002356.  PMID:29176388. 
Gibala MJ, MacLean DA, Graham TE,  Saltin B. 1998. Tricarboxylic acid cycle 
intermediate pool size and estimated cycle flux in human muscle during exercise. Am 
J Physyiol-Endoc M, 275 (2): E235-E242. 
Glenn JM, Gray M, Wethington LN, Stone MS, Stewart RWJr, Moyen NE. 2017. 
Acute citrulline malate supplementation improves upper- and lower-body submaximal 
weightlifting exercise performance in resistance-trained females. Eur J Nutr, 56(2): 
775-784. 
Hickner RC, Tanner CJ, Evans CA, Clark PD, Haddock A, Fortune C, Geddis H, 
Mccammon M. 2006. L-citrulline reduces time to exhaustion and insulin response to 
a graded exercise test. Med Sci Sport Exer, 38(4): 660-666. 
Kiyici F, Eroğlu H, Kishali NF, Burmaoglu G. 2017. The effect of citrulline/malate on 
blood lactate levels in intensive exercise. Biochem Genet, 55(5-6): 387-394. 
19 
 
Kuhn KP, Harris PA, Cunningham GR, Robbins IM, Summar ML, Christman BW. 
2002. Oral citrulline effectively elevates plasma arginine levels for 24 h in normal 
volunteers. Circulation, 106(II): 1-766S. 
Meneguello MO, Mendonca J, Lancha AH, Costa Rosa L FBP. 2003. Effect of 
arginine, ornithine and citrulline supplementation upon performance and metabolism 
of trained rats. Cell Biochem Funct, 21(1): 85-91. 
Moinard C, Nicolis I, Neveux N, Darquy S, Bénazeth S, Cynober L. 2008. Dose-
ranging effects of citrulline administration on plasma amino acids and hormonal 
patterns in healthy subjects: the Citrudose pharmacokinetic study. Brit J Nutr, 99(4): 
855-862.  
National Strength and Conditioning Association. Program design and technique for 
speed and agility training. 2015. In: Haff G, Triplett NT, editors. Essentials of Strength 
Training & Conditioning. Champaign, IL (USA): Human Kinetics. p. 543. 
Ochiai M, Hayashi T, Morita M, Ina K, Maeda M, Watanabe F, Morishita K. 2012. 
Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged 
men. Int J Cardiol, 155(2): 257-261. 
Perez-Guisado J, Jakeman PM. 2010. Citrulline malate enhances athletic anaerobic 
performance and relieves muscle soreness. J Strength Cond Res, 24(5): 1215-1222. 
Petrović V, Buzadžić B, Korać A, Vasilijević A, Janković A, Mićunović K, Korać B. 
2008. Antioxidative defence alterations in skeletal muscle during prolonged 
acclimation to cold: role of L-arginine/NO-producing pathway. J Exp Biol, 211(1): 
114-120. 
20 
 
Romero MJ, Platt DH, Caldwell RB, Caldwell RW. 2006. Therapeutic use of citrulline 
in cardiovascular disease. Cardiovasc Ther, 24(3-4): 275-290. 
Schwedhelm E, Maas R, Freese R, Jung D, Lukacs Z, Jambrecina A, Spickler W, 
Schulze F, Boger RH. 2007 Pharmacokinetic and pharmaxodynamic properties of 
oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin 
Pharmacol, 65 (1): 51-59 
Sugino T, Aoyagi S, Shirai T, Kajimoto Y, Kajimoto O. 2007. Effects of citric acid and 
L-carnitine on physical fatigue. J clin biochem nutr, 41(3): 224-230. 
Sureda A, Cordova A, Ferrer MD, Perez G, Tur JA, Pons A. 2010.  L-citrulline-malate 
influence over branched chain amino acid utilization during exercise.  Eur J App 
Physiol, 110(2): 341-351. 
Takeda K, Machida M, Kohara A, Omi N, Takemasa T. 2011. Effects of citrulline 
supplementation on fatigue and exercise performance in mice. J Nutr Sci Vitaminol, 
57(3): 246-250. 
Tarazona-Díaz MP, Alacid F, Carrasco M, Martínez I, Aguayo E. 2013. Watermelon 
juice: potential functional drink for sore muscle relief in athletes. J Agr Food Chem, 
61(31): 7522-7528. 
Thomas C, Sirvent P, Perrey S, Raynaud E, Mercier J. 2004. Relationships between 
maximal muscle oxidative capacity and blood lactate removal after supramaximal 
exercise and fatigue indexes in humans. J Appl Physiol, 97(6): 2132-2138. 
Vanuxem D, Duflot JC, Prevot H, Bernasconi P, Blehaut H, Fornaris E, Vanuxem P. 
1990. Influence of an anti-asthenia agent, citrulline malate, on serum lactate and 
21 
 
ammonia kinetics during a maximum exercise test in sedentary subjects. Sem Hop 
Paris, 66(9): 477-481. 
Wagenmakers AJ. 1998. Muscle amino acid metabolism at rest and during exercise: 
role in human physiology and metabolism. Exercise Sport Sci R, 26: 287-314. 
Wax B, Kavazis AN, Weldon K, Sperlak J. 2015. Effects of supplemental citrulline 
malate ingestion during repeated bouts of lower-body exercise in advanced 
weightlifters. J Strength Cond Res, 29(3): 786-792. 
Wax B, Kavazis AN, Luckett W. 2016. Effects of supplemental citrulline-malate 
ingestion on blood lactate, cardiovascular dynamics, and resistance exercise 
performance in trained males. J Diet Suppl, 13(3): 269-282. 
Wijnands KA, Castermans TM, Hommen MP, Meesters DM, Poeze M. 2015. Arginine 
and citrulline and the immune response in sepsis. Nutrients, 7(3): 1426-1463. 
  
22 
 
Tables 
Table 1 Participant Characteristics (n - 19, 12 male, 7 female)  
Age (years) Height (m) Weight (kg) BMI (kg/m2) Bodyfat (%) 
25.7 ± 7.7 1.7 ± 0.1 75.3 ± 13.7 24.8 ± 2.9 18.3 ± 5.8 
Abbreviations: m, metres; kg, kilogram; BMI, body mass index. 
All values are mean ± SD  
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Table 2. 24 Hour Dietary Intakes Preceding the German Volume Training 
 Placebo Citrulline 
Malate 
P value 
Carbohydrate (g / kg BW) 3.8 ± 1.8 3.2 ± 1.7 0.285 
Protein (g / kg BW) 2.2 ± 1.5 1.8 ± 0.9 0.575 
Fat (g / kg BW) 1.0 ± 0.4 0.9 ± 0.4 0.223 
Energy (Kcal / kg BW) 34.6 ± 10.7 28.8 ± 10.7 0.730 
Abbreviations: g, grams; kg, kilograms, BW, bodyweight; Kcal, calories. 
 (Paired t-test: Fat; Wilcoxon Signed Rank Carbohydrate, Protein and Energy). All values are means ± 
SD, 
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Legends for Figures 
Figure 1 - The effect of citrulline malate on resistance training performance. Exercise performance 
with the placebo is represented by the solid black line (n = 19); citrulline malate is represented by the 
dashed line (n = 19). (repeated measures ANOVA time p < 0.05; treatment × time × order p > 0.05) 
The data presented is the mean ± SD.  
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Figure 2 - The effect of citrulline malate on blood lactate following resistance training. Pre-exercise 
lactate values are represented by the grey bars (n = 18); post-exercise values are represented by the 
black bars (n = 18); the white bars represent the magnitude of change between placebo and 
supplement (n = 18). Results analysed using a paired t-test, * indicates significant difference pre to 
post exercise. The data presented is the mean ± SD.  
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Figure 3 - The effect of citrulline malate on muscle soreness following resistance training. Muscle 
soreness with the placebo is represented by the solid black line (n = 19); citrulline malate is 
represented by the dashed line (n = 19). Over time muscle soreness was significantly higher in the 
placebo compared to citrulline malate treatment (repeated measures ANOVA: treatment × time × 
order p = 0.008). The data presented is the mean ± SD. 
 
